Shanghai, China

Lei Shan

This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd., East China University of Science and Technology, The Second Military Medical University. Active years: 2014-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lei Shan. Retrieved from https://idiyas.com/inventor/lei-shan-srou00h9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 66.7

 

Average Co-Inventor Count = 8.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Lei Shan in Myocarditis and Multiple Sclerosis Treatment

Introduction

Lei Shan is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of medical science, particularly in the treatment of myocarditis and multiple sclerosis. With a total of three patents to his name, his work focuses on the therapeutic potential of line leaf inula flower lactone A.

Latest Patents

Lei Shan's latest patents include "Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis" and "Preparation and application of line leaf flower lactone A for treating multiple sclerosis." The compound line leaf flower lactone A has shown positive therapeutic activity against the Coxsackie virus and demonstrates a significant dose-dependent correlation. In mouse models of experimental autoimmune myocarditis, the compound prevents disease onset when administered intraperitoneally at a dose of 20 mg/kg/d. Increasing the dosage to 100 mg/kg/d enhances its therapeutic effects on experimental autoimmune myocarditis. The line leaf flower lactone A can be formulated as a pharmaceutical composition in various forms, including tablets, capsules, injections, and aerosols. Additionally, it has therapeutic effects on experimental autoimmune encephalomyelitis, making it a promising candidate for developing drugs to treat multiple sclerosis.

Career Highlights

Throughout his career, Lei Shan has worked with notable organizations, including Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd. and the Second Military Medical University. His research has focused on the development of innovative treatments that leverage the unique properties of line leaf flower lactone A.

Collaborations

Lei Shan has collaborated with several professionals in his field, including Weidong Zhang and Juan Su, who is a prominent female researcher. Their combined expertise has contributed to the advancement of research in therapeutic applications.

Conclusion

Lei Shan's innovative work in the development of line leaf flower lactone A represents a significant advancement in the treatment of myocarditis and multiple sclerosis. His contributions to medical science highlight the importance of research and innovation in addressing complex health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…